SCHEMBL7348016

SCHEMBL7348016

O=CCCCCCC1CCCCC1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.54
CYP1A2 P05177 1/20 0.46
ADH1B P00325 1/20 0.43
ADH1C P00326 1/20 0.43
ADH1A P07327 1/20 0.43
ADH4 P08319 1/20 0.43
ADH7 P40394 1/20 0.43
GPR84 Q9NQS5 1/20 0.41
KDM5A P29375 3/20 0.40
PHF8 Q9UPP1 3/20 0.40
KDM2A Q9Y2K7 3/20 0.40
KDM4C Q9H3R0 2/20 0.40
KDM4A O75164 1/20 0.40
TSHR P16473 1/20 0.39
EPHX1 P07099 1/20 0.39
HIF1A Q16665 1/20 0.38
NAAA Q02083 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10684366 1.00 SIGMAR1 (0.54) SIGMAR1CYP1A2ADH1BADH1CADH1A
SCHEMBL14607493 1.00 SIGMAR1 (0.54) SIGMAR1CYP1A2ADH1BADH1CADH1A
SCHEMBL2178636 1.00 SIGMAR1 (0.54) SIGMAR1CYP1A2ADH1BADH1CADH1A
SCHEMBL98104 1.00 SIGMAR1 (0.54) SIGMAR1CYP1A2ADH1BADH1CADH1A
SCHEMBL8814716 1.00 SIGMAR1 (0.54) SIGMAR1CYP1A2ADH1BADH1CADH1A
Water SCHEMBL28376340 0.98 SIGMAR1 (0.52) SIGMAR1CYP1A2ADH1BADH1CADH1A
SCHEMBL97095 0.98 SIGMAR1 (0.50) SIGMAR1CYP1A2ADH1BADH1CADH1A
SCHEMBL11102125 0.98 SIGMAR1 (0.50) SIGMAR1CYP1A2ADH1BADH1CADH1A
SCHEMBL7350454 0.98 SIGMAR1 (0.50) SIGMAR1CYP1A2ADH1BADH1CADH1A
SCHEMBL11151075 0.98 SIGMAR1 (0.50) SIGMAR1CYP1A2ADH1BADH1CADH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282818-A1 SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF UNIVERSITY OF FLORIDA RESEARCH FOUNDATION,INCORPORATED (US) 2025-09-11 US disclosed
WO-2023211883-A1 SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-11-02 WO disclosed
WO-2023211883-A1 SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-11-02 WO disclosed
US-5985869-A USEFUL AS VASODILATORS, HYPOTENSIVE AGENTS, WATER DIURETICS, PLATELET AGGLUTINATION INHIBITORS OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1999-11-16 US disclosed
US-5753677-A Benzoheterocyclic compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1998-05-19 US disclosed
US-5559230-A VASOPRESSIN ANTAGONISTS, QUINOLINES, BENZAZEPINES, VASODILATION, HYPOTENSIVE AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1996-09-24 US disclosed
EP-0450097-B1 BENZOHETEROCYCLIC COMPOUNDS OTSUKA PHARMA CO LTD (JP) 1996-04-24 EP disclosed
EP-0602209-A1 OXYTOCIN ANTAGONIST OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-06-22 EP disclosed
WO-1994001113-A1 OXYTOCIN ANTAGONIST OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1994-01-20 WO disclosed
EP-0450097-A1 BENZOHETEROCYCLIC COMPOUNDS. OTSUKA PHARMA CO LTD (JP) 1991-10-09 EP disclosed
WO-1991005549-A1 BENZOHETEROCYCLIC COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282818-A1 SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF PSMB10, PSMB1, PSMB5 SIGMAR1 4031/4885CYP1A2 4409/4885ADH1B 3312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.